Beludavimab

DB18952InvestigationalProtein Based Therapies

Beludavimab is under investigation in clinical trial NCT04746183 (AGILE (Early Phase Platform Trial for COVID-19)).

Mechanism
Curator reviewed
Also known as
IMMUNOGLOBULIN G1 (246-ALANINE,340-LEUCINE,342-GLUTAMIC ACID,438-LEUCINE,444-SERINE), ANTI-(SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 SPIKE GLYCOPROTEIN RECEPTOR-BINDING DOMAIN) (HUMAN MONOCLONAL VIR-7832 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOC
Code names
GSK-4182137 · VIR-7832

Resolves to

Compound
UNIIFM2MK5954WCAS2423016-74-2
Targets
P0DTC2S

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
1Clinical trialPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with Beludavimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In